Abdulrahman Katib on API-CAT Trial’s Evaluation of Apixaban Dosing
Abdulrahman Katib, Internal Medicine and Adult Thrombosis Consultant at King Faisal Specialist Hospital and Research Center, shared on LinkedIn:
”Cancer-associated thrombosis (CAT) remains one of the highest-risk VTE settings, where we constantly balance recurrent VTE prevention against bleeding risk.
API-CAT evaluated whether a reduced-dose apixaban strategy could maintain efficacy while improving safety during extended anticoagulation.
The trial showed that a lower dose of apixaban (2.5 mg BID) was non-inferior to the standard dose (5 mg BID) for preventing recurrent VTE in patients with active cancer, and it was associated with less bleeding.”
Read the full article here.
Article: Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism
Authors: Isabelle Mahé, Marc Carrier, Didier Mayeur, Jean Chidiac, Eric Vicaut, Nicolas Falvo, Olivier Sanchez et al., for the API-CAT Investigators
Stay updated on all scientific advances with Hemostasis Today.
-
May 12, 2026, 16:46Tagreed Alkaltham: Why Apheresis Matters in Modern Transfusion Medicine
-
May 12, 2026, 16:37Reinhold Kreutz: Cardiovascular Burden in Acute Intermittent Porphyria Needs Greater Awareness
-
May 12, 2026, 16:33Pablo Corral: The Truth About Very Low LDL-Cholesterol
-
May 12, 2026, 16:24Mildred Lundgren: We Must Talk About the Invisible Causes of Stroke
-
May 12, 2026, 16:17Irene Scala: The Sex Disparities In Access to Acute Stroke Treatments In Italy
-
May 12, 2026, 16:04May Nour: UCLA Health Mobile Stroke Unit Becomes The 1st In The World to Perform mCTA In the Field
-
May 12, 2026, 15:57Leonardo Roever: Prognostic Impact of Lipoprotein(a) and CAR in Elderly Acute Ischemic Stroke Patients
-
May 12, 2026, 15:54Bruno Pougault: Prioritizing Laboratory Tests in Resource-Limited Emergency Care
-
May 12, 2026, 15:37Jennifer Holter Chakrabarty: Supporting the Next Generation of Hematology Researchers